97 results on '"Gómez, Carmen Elena"'
Search Results
2. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium
- Author
-
Marcos-Villar, Laura, Perdiguero, Beatriz, Anthiya, Shubaash, Borrajo, Mireya L., Lou, Gustavo, Franceschini, Lorenzo, Esteban, Ignasi, Sánchez-Cordón, Pedro J., Zamora, Carmen, Sorzano, Carlos Óscar S., Jordá, Luis, Codó, Laia, Gelpí, Josep L., Sisteré-Oró, Marta, Meyerhans, Andreas, Thielemans, Kris, Martínez-Jiménez, Francisco, López-Bigas, Núria, García, Felipe, Alonso, María J., Plana, Montserrat, Esteban, Mariano, and Gómez, Carmen Elena
- Published
- 2024
- Full Text
- View/download PDF
3. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
- Author
-
Perdiguero, Beatriz, Pérez, Patricia, Marcos-Villar, Laura, Albericio, Guillermo, Astorgano, David, Álvarez, Enrique, Sin, Laura, Gómez, Carmen Elena, García-Arriaza, Juan, and Esteban, Mariano
- Published
- 2023
- Full Text
- View/download PDF
4. Unveiling the Multifaceted Roles of ISG15: From Immunomodulation to Therapeutic Frontiers.
- Author
-
Álvarez, Enrique, Falqui, Michela, Sin, Laura, McGrail, Joseph Patrick, Perdiguero, Beatriz, Coloma, Rocío, Marcos-Villar, Laura, Tárrega, Céline, Esteban, Mariano, Gómez, Carmen Elena, and Guerra, Susana
- Subjects
DNA repair ,IMMUNOREGULATION ,IMMUNE response ,VACCINE development ,VIRAL antigens ,AUTOPHAGY - Abstract
The Interferon Stimulated Gene 15 (ISG15), a unique Ubiquitin-like (Ubl) modifier exclusive to vertebrates, plays a crucial role in the immune system. Primarily induced by interferon (IFN) type I, ISG15 functions through diverse mechanisms: (i) covalent protein modification (ISGylation); (ii) non-covalent intracellular action; and (iii) exerting extracellular cytokine activity. These various roles highlight its versatility in influencing numerous cellular pathways, encompassing DNA damage response, autophagy, antiviral response, and cancer-related processes, among others. The well-established antiviral effects of ISGylation contrast with its intriguing dual role in cancer, exhibiting both suppressive and promoting effects depending on the tumour type. The multifaceted functions of ISG15 extend beyond intracellular processes to extracellular cytokine signalling, influencing immune response, chemotaxis, and anti-tumour effects. Moreover, ISG15 emerges as a promising adjuvant in vaccine development, enhancing immune responses against viral antigens and demonstrating efficacy in cancer models. As a therapeutic target in cancer treatment, ISG15 exhibits a double-edged nature, promoting or suppressing oncogenesis depending on the tumour context. This review aims to contribute to future studies exploring the role of ISG15 in immune modulation and cancer therapy, potentially paving the way for the development of novel therapeutic interventions, vaccine development, and precision medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA).
- Author
-
Esteban, Ignasi, Pastor-Quiñones, Carmen, Usero, Lorena, Aurrecoechea, Elena, Franceschini, Lorenzo, Esprit, Arthur, Gelpí, Josep Lluís, Martínez-Jiménez, Francisco, López-Bigas, Núria, Breckpot, Karine, Thielemans, Kris, Leal, Lorna, Gómez, Carmen Elena, Sisteré-Oró, Marta, Meyerhans, Andreas, Esteban, Mariano, Alonso, María José, García, Felipe, and Plana, Montserrat
- Subjects
MONONUCLEAR leukocytes ,T cells ,MESSENGER RNA ,VIRAL proteins ,PROTEIN receptors - Abstract
The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we present two new mRNAs expressing antigenic parts of the SARS-CoV-2 spike protein and provide data supporting their functionality. The first mRNA, called RBD-mRNA, encodes a trimeric form of the virus spike protein receptor binding domain (RBD). The other mRNA, termed T-mRNA, codes for the relevant HLA I and II spike epitopes. The two mRNAs (COVARNA mRNAs) were designed to be used for delivery to cells in combination, with the RBD-mRNA being the primary source of antigen and the T-mRNA working as an enhancer of immunogenicity by supporting CD4 and CD8 T-cell activation. This innovative approach substantially differs from other available mRNA vaccines, which are largely directed to antibody production by the entire spike protein. In this study, we first show that both mRNAs are functionally transfected into human antigen-presenting cells (APCs). We obtained peripheral blood mononuclear cell (PBMC) samples from three groups of voluntary donors differing in their immunity against SARS-CoV-2: non-infected (naïve), infected-recovered (convalescent), and vaccinated. Using an established method of co-culturing autologous human dendritic cells (hDCs) with T-cells, we detected proliferation and cytokine secretion, thus demonstrating the ability of the COVARNA mRNAs to activate T-cells in an antigen-specific way. Interestingly, important differences in the intensity of the response between the infected-recovered (convalescent) and vaccinated donors were observed, with the levels of T-cell proliferation and cytokine secretion (IFNγ, IL-2R, and IL-13) being higher in the vaccinated group. In summary, our data support the further study of these mRNAs as a combined approach for future use as a vaccine. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. NFκB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses
- Author
-
Di Pilato, Mauro, Mejías-Pérez, Ernesto, Zonca, Manuela, Perdiguero, Beatriz, Gómez, Carmen Elena, Trakala, Marianna, Nieto, Jacobo, Nájera, José Luis, Sorzano, Carlos Oscar S., Combadière, Christophe, Pantaleo, Giuseppe, Planelles, Lourdes, and Esteban, Mariano
- Published
- 2015
7. Immunogenicity and efficacy of a novel multi-patch SARS-CoV-2/COVID-19 vaccine candidate.
- Author
-
Perdiguero, Beatriz, Marcos-Villar, Laura, López-Bravo, María, Sánchez-Cordón, Pedro J., Zamora, Carmen, Ramón Valverde, José, Sorzano, Carlos Óscar S., Sin, Laura, Álvarez, Enrique, Ramos, Manuel, Del Val, Margarita, Esteban, Mariano, and Gómez, Carmen Elena
- Subjects
IMMUNE response ,VIRAL antigens ,CYTOSKELETAL proteins ,ANTIGEN presentation ,VACCINIA - Abstract
Introduction: While there has been considerable progress in the development of vaccines against SARS-CoV-2, largely based on the S (spike) protein of the virus, less progress has been made with vaccines delivering different viral antigens with cross-reactive potential. Methods: In an effort to develop an immunogen with the capacity to induce broad antigen presentation, we have designed a multi-patch synthetic candidate containing dominant and persistent B cell epitopes from conserved regions of SARS-CoV-2 structural proteins associated with long-term immunity, termed CoV2-BMEP. Here we describe the characterization, immunogenicity and efficacy of CoV2-BMEP using two delivery platforms: nucleic acid DNA and attenuated modified vaccinia virus Ankara (MVA). Results: In cultured cells, both vectors produced a main protein of about 37 kDa as well as heterogeneous proteins with size ranging between 25-37 kDa. In C57BL/6 mice, both homologous and heterologous prime/boost combination of vectors induced the activation of SARS-CoV-2-specific CD4 and CD8 T cell responses, with a more balanced CD8
+ T cell response detected in lungs. The homologous MVA/MVA immunization regimen elicited the highest specific CD8+ T cell responses in spleen and detectable binding antibodies (bAbs) to S and N antigens of SARS-CoV-2. In SARS-CoV-2 susceptible k18-hACE2 Tg mice, two doses of MVA-CoV2-BMEP elicited S- and N-specific bAbs as well as crossneutralizing antibodies against different variants of concern (VoC). After SARSFrontiers CoV-2 challenge, all animals in the control unvaccinated group succumbed to the infection while vaccinated animals with high titers of neutralizing antibodies were fully protected against mortality, correlating with a reduction of virus infection in the lungs and inhibition of the cytokine storm. Discussion: These findings revealed a novel immunogen with the capacity to control SARS-CoV-2 infection, using a broader antigen presentation mechanism than the approved vaccines based solely on the S antigen. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses.
- Author
-
Usero, Lorena, Leal, Lorna, Gómez, Carmen Elena, Miralles, Laia, Aurrecoechea, Elena, Esteban, Ignasi, Torres, Berta, Inciarte, Alexy, Perdiguero, Beatriz, Esteban, Mariano, García, Felipe, and Plana, Montserrat
- Subjects
NEGATIVE regulatory factor ,IMMUNE response ,TOLL-like receptors ,T cells ,MESSENGER RNA - Abstract
The development of new strategies to achieve a functional cure for HIV remains a priority. We tested a novel HIV therapeutic vaccine using unmodified mRNA (TMEP-B) and mRNA modified by 1-methyl-3′-pseudouridylyl (TMEP-Bmod) expressing both a multiepitopic sequences from Gag, Pol, and Nef proteins, including different CD4 and CD8 T-cell epitopes functionally associated with HIV control in transfected monocyte-derived dendritic cells (MDDCs) obtained from HIV infected patients. In vitro assays were used to test the mRNAs alone and in combination with immunomodulator agents, such as the TLR-7 agonist Vesatolimod and the PD-1 antagonist Nivolumab to try to improve HIV-specific cellular immune responses. Combining the mRNAs with the immunomodulators enhanced HIV-specific T-cell responses, together with the secretion of IFNγ, IP10, MIP-1α, and MIP-1β, which are fundamental mediators of viral control. Our data suggest that the mRNA vaccine prototypes TMEP-B and TMEP-Bmod, when combined with Vesatolimod and/or Nivolumab, could achieve functional cure for patients with HIV. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1
- Author
-
Mothe, Beatriz, Climent, Nuria, Plana, Montserrat, Rosàs, Miriam, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Puertas, María C., Carrillo, Jorge, Gonzalez, Nuria, León, Agathe, Pich, Judit, Arnaiz, Joan Albert, Gatell, Jose M., Clotet, Bonaventura, Blanco, Julià, Alcamí, José, Martinez-Picado, Javier, Alvarez-Fernández, Carmen, Sánchez-Palomino, Sonsoles, Guardo, Alberto C., Peña, José, Benito, José M., Rallón, Norma, Gómez, Carmen E., Perdiguero, Beatriz, García-Arriaza, Juan, Esteban, Mariano, López Bernaldo de Quirós, Juan Carlos, Brander, Christian, García, Felipe, Mothe, Beatriz, Cobarsi, Patricia, Rosàs, Miriam, Puertas, María C., Carrillo, Jorge, Blanco, Juliá, Martinez-Picado, Javier, Clotet, Bonaventura, Brander, Christian, Climent, Nuria, Plana, Montserrat, Alvarez, Carmen, Sánchez, Sonsoles, León, Agathe, Pich, Judit, Arnaiz, Joan Albert, Leal, Lorna, Torres, Berta, Lucero, Constanza, Guardo, Alberto C., Gatell, Jose M., García, Felipe, Jiménez, José Luis, Muñoz-Fernández, María Angeles, López Bernaldo de Quirós, Juan Carlos, Esteban, Mariano, Gómez, Carmen Elena, Perdiguero, Beatriz, García-Arriaza, Juan, Cepeda, Victoria, Sánchez-Sorzano, Carlos Oscar, Gonzalez, Nuria, Alcamí, José, Jiménez, Laura, Benito, José M., Rallón, Norma, and Peña, José
- Published
- 2015
- Full Text
- View/download PDF
10. Clinical applications of attenuated MVA poxvirus strain
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, García-Arriaza, Juan, and Esteban, Mariano
- Published
- 2013
- Full Text
- View/download PDF
11. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1 BX08 gp120 and HIV-1 IIIB Gag-Pol-Nef proteins of clade B
- Author
-
Gómez, Carmen Elena, Nájera, Jose Luis, Jiménez, Eva Pérez, Jiménez, Victoria, Wagner, Ralf, Graf, Marcus, Frachette, Marie-Joelle, Liljeström, Peter, Pantaleo, Giuseppe, and Esteban, Mariano
- Published
- 2007
- Full Text
- View/download PDF
12. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C
- Author
-
Gómez, Carmen Elena, Nájera, Jose Luis, Jiménez, Victoria, Bieler, Kurt, Wild, Jens, Kostic, Linda, Heidari, Shirin, Chen, Margaret, Frachette, Marie-Joelle, Pantaleo, Giuseppe, Wolf, Hans, Liljeström, Peter, Wagner, Ralf, and Esteban, Mariano
- Published
- 2007
- Full Text
- View/download PDF
13. Poxvirus vectors as HIV/AIDS vaccines in humans
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, García-Arriaza, Juan, and Esteban, Mariano
- Published
- 2012
14. Enhanced CD8 + T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: a comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector
- Author
-
Gómez, Carmen Elena, Rodrı́guez, Dolores, Rodrı́guez, Juan Ramón, Abaitua, Fernando, Duarte, Carlos, and Esteban, Mariano
- Published
- 2001
- Full Text
- View/download PDF
15. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
- Author
-
Perdiguero, Beatriz, Gómez, Carmen Elena, García-Arriaza, Juan, Sánchez-Corzo, Cristina, Sorzano, Carlos Óscar S., Wilmschen, Sarah, von Laer, Dorothee, Asbach, Benedikt, Schmalzl, Christina, Peterhoff, David, Ding, Song, Wagner, Ralf, Kimpel, Janine, Levy, Yves, Pantaleo, Giuseppe, and Esteban, Mariano
- Subjects
T cells ,B cells ,T helper cells ,IMMUNE response ,HUMORAL immunity ,AIDS vaccines ,CD19 antigen - Abstract
The generation of a vaccine against HIV-1 able to induce durable protective immunity continues a major challenge. The modest efficacy (31.2%) of the phase III RV144 clinical trial provided the first demonstration that a prophylactic HIV/AIDS vaccine is achievable but emphasized the need for further refinements of vaccine candidates, formulations, and immunization regimens. Here, we analyzed in mice the immunogenicity profile elicited by different homologous and heterologous prime/boost combinations using the modified rhabdovirus VSV-GP combined with DNA or poxviral NYVAC vectors, all expressing trimeric membrane-bound Env (gp145) of HIV-1 96ZM651 clade C, with or without purified gp140 protein component. In cultured cells infected with recombinant VSV-GP or NYVAC viruses, gp145 epitopes at the plasma membrane were recognized by human HIV-1 broadly neutralizing antibodies (bNAbs). In immunized mice, the heterologous combination of VSV-GP and NYVAC recombinant vectors improved the induction of HIV-1 Env-specific humoral and cellular immune responses compared to homologous prime/boost protocols. Specifically, the combination of VSV-GP in the prime and NYVAC in the boost induced higher HIV-1 Env-specific T cell (CD4/CD8 T cells and T follicular helper -Tfh- cells) immune responses compared to the use of DNA or NYVAC vectors in the prime and VSV-GP in the boost. Such enhanced T cell responses correlated with an enhancement of the Env-specific germinal center (GC) B cell population and with a heavily biased Env-specific response toward the Th1-associated IgG2a and IgG3 subclasses, while the other groups showed a Th2-associated IgG1 bias. In summary, our T and B cell population data demonstrated that VSV-GP-based vectors could be taken into consideration as an optimized immunogenic HIV-1 vaccine candidate component against HIV-1 when used for priming in heterologous combinations with the poxvirus vector NYVAC as a boost. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, Sánchez-Corzo, Cristina, Sorzano, Carlos Oscar S., and Esteban, Mariano
- Subjects
- *
HIV infections , *THERAPEUTICS , *AIDS vaccines , *VIRAL genes , *DELETION mutation , *IMMUNOREGULATION , *VIRUSES - Abstract
An HIV-1 vaccine continues to be a major target to halt the AIDS pandemic. The limited efficacy of the RV144 phase III clinical trial with the canarypox virus-based vector ALVAC and a gp120 protein component led to the conclusion that improved immune responses to HIV antigens are needed for a more effective vaccine. In non-human primates, the New York vaccinia virus (NYVAC) poxvirus vector has a broader immunogenicity profile than ALVAC and has been tested in clinical trials. We therefore analysed the HIV immune advantage of NYVAC after removing viral genes that act on several signalling pathways (Toll-like receptors--TLR--interferon, cytokines/chemokines), as well as genes of unknown immune function. We generated a series of NYVAC deletion mutants and studied immune behaviour (T and B cell) to HIV antigens and to the NYVAC vector in mice. Our results showed that combined deletion of selected vaccinia virus (VACV) genes is a valuable strategy for improving the immunogenicity of NYVAC-based vaccine candidates. These immune responses were differentially modulated, positive or negative, depending on the combination of gene deletions. The deletions also led to enhanced antigen- or vector-specific cellular and humoral responses. These findings will facilitate the development of optimal NYVAC-based vaccines for HIV and other diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
17. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Author
-
C. Guardo, Alberto, Gómez, Carmen Elena, Díaz-Brito, Vicens, Pich, Judit, Arnaiz, Joan Albert, Perdiguero, Beatriz, García-Arriaza, Juan, González, Nuria, Sorzano, Carlos O. S., Jiménez, Laura, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Gatell, José M, Alcamí, José, Esteban, Mariano, López Bernaldo de Quirós, Juan Carlos, García, Felipe, Plana, Montserrat, and null, null
- Subjects
- *
VACCINES , *AIDS vaccines , *IMMUNE response , *HUMORAL immunity , *IMMUNIZATION , *ANTIBODY formation , *T cells - Abstract
Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost. Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost. Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively. Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector. Trial registration: ClinicalTrials.gov . [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. A Phase I Randomized Therapeutic MVA-B Vaccination Improves the Magnitude and Quality of the T Cell Immune Responses in HIV-1-Infected Subjects on HAART.
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, García-Arriaza, Juan, Cepeda, Victoria, Sánchez-Sorzano, Carlos Óscar, Mothe, Beatriz, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Gatell, Jose M., López Bernaldo de Quirós, Juan Carlos, Brander, Christian, García, Felipe, and Esteban, Mariano
- Subjects
- *
T cells , *DIAGNOSIS of HIV infections , *ANTIGENS , *CLINICAL trials , *INTRACELLULAR membranes - Abstract
Trial Design: Previous studies suggested that poxvirus-based vaccines might be instrumental in the therapeutic HIV field. A phase I clinical trial was conducted in HIV-1-infected patients on highly active antiretroviral therapy (HAART), with CD4 T cell counts above 450 cells/mm3 and undetectable viremia. Thirty participants were randomized (2:1) to receive either 3 intramuscular injections of MVA-B vaccine (coding for clade B HIV-1 Env, Gag, Pol and Nef antigens) or placebo, followed by interruption of HAART. Methods: The magnitude, breadth, quality and phenotype of the HIV-1-specific T cell response were assayed by intracellular cytokine staining (ICS) in 22 volunteers pre- and post-vaccination. Results: MVA-B vaccine induced newly detected HIV-1-specific CD4 T cell responses and expanded pre-existing responses (mostly against Gag, Pol and Nef antigens) that were high in magnitude, broadly directed and showed an enhanced polyfunctionality with a T effector memory (TEM) phenotype, while maintaining the magnitude and quality of the pre-existing HIV-1-specific CD8 T cell responses. In addition, vaccination also triggered preferential CD8+ T cell polyfunctional responses to the MVA vector antigens that increase in magnitude after two and three booster doses. Conclusion: MVA-B vaccination represents a feasible strategy to improve T cell responses in individuals with pre-existing HIV-1-specific immunity. Trial Registration: ClinicalTrials.gov [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles.
- Author
-
Gómez, Carmen Elena, Cepeda, Victoria, Sánchez-Sampedro, Lucas, García-Arriaza, Juan, Mejías-Pérez, Ernesto, Jiménez, Victoria, Sánchez, Cristina, Sorzano, Carlos Óscar S., Oliveros, Juan Carlos, Delaloye, Julie, Roger, Thierry, Calandra, Thierry, Asbach, Benedikt, Wagner, Ralf, Kibler, Karen V., Jacobs, Bertram L., Pantaleo, Giuseppe, and Esteban, Mariano
- Subjects
- *
AIDS vaccination research , *HIV infections -- Immunological aspects , *VIRUS-like particles , *VIROLOGY -- Technique , *HIV seronegativity , *IMMUNITY - Abstract
The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2%) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol-Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens.
- Author
-
Sánchez-Sampedro, Lucas, Gómez, Carmen Elena, Mejías-Pérez, Ernesto, Pérez-Jiménez, Eva, Oliveros, Juan Carlos, and Esteban, Mariano
- Subjects
- *
VACCINIA , *PATHOGENIC microorganisms , *VIRAL replication , *ACUTE erythroid leukemia , *GENETIC mutation , *ANTIGENS , *PHENOTYPES - Abstract
Replication-competent poxvirus vectors with an attenuation phenotype and with a high immunogenic capacity of the foreign expressed antigen are being pursued as novel vaccine vectors against different pathogens. In this investigation, we have examined the replication and immunogenic characteristics of two vaccinia virus (VACV) mutants, M65 and M101. These mutants were generated after 65 and 101 serial passages of persistently infected Friend erythroleukemia (FEL) cells. In cultured cells of different origins, the mutants are replication competent and have growth kinetics similar to or slightly reduced in comparison with those of the parental Western Reserve (WR) virus strain. In normal and immune-suppressed infected mice, the mutants showed different levels of attenuation and pathogenicity in comparison with WR and modified vaccinia Ankara (MVA) strains. Wide genome analysis after deep sequencing revealed selected genomic deletions and mutations in a number of viral open reading frames (ORFs). Mice immunized in a DNA prime/mutant boost regimen with viral vectors expressing the LACK (Leishmania homologue for receptors of activated C kinase) antigen of Leishmania infantum showed protection or a delay in the onset of cu-taneous leishmaniasis. Protection was similar to that triggered by MVA-LACK. In immunized mice, both polyfunctional CD4+ and CD8+ T cells with an effector memory phenotype were activated by the two mutants, but the DNA-LACK/M65-LACK protocol preferentially induced CD4+ whereas DNA-LACK/M101-LACK preferentially induced CD8+ T cell responses. Altogether, our findings showed the adaptive changes of the WR genome during long-term virus-host cell interaction and how the replication competency of M65 and M101 mutants confers distinct biological properties and immunogenicity in mice compared to those of the MVA strain. These mutants could have applicability for understanding VACV biology and as potential vaccine vectors against pathogens and tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Deletion of the Viral Anti-Apoptotic Gene F1L in the HIV/AIDS Vaccine Candidate MVA-C Enhances Immune Responses against HIV-1 Antigens.
- Author
-
Perdiguero, Beatriz, Gómez, Carmen Elena, Nájera, Jose Luis, Sorzano, Carlos Oscar S., Delaloye, Julie, González-Sanz, Rubén, Jiménez, Victoria, Roger, Thierry, Calandra, Thierry, Pantaleo, Giuseppe, and Esteban, Mariano
- Subjects
- *
VACCINIA , *BCL-2 proteins , *CASPASES , *IMMUNE response , *DENDRITIC cells , *T cells - Abstract
Vaccinia virus (VACV) encodes an anti-apoptotic Bcl-2-like protein F1 that acts as an inhibitor of caspase-9 and of the Bak/Bax checkpoint but the role of this gene in immune responses is not known. Because dendritic cells that have phagocytosed apoptotic infected cells cross-present viral antigens to cytotoxic T cells inducing an antigen-specific immunity, we hypothesized that deletion of the viral anti-apoptotic F1L gene might have a profound effect on the capacity of poxvirus vectors to activate specific immune responses to virus-expressed recombinant antigens. This has been tested in a mouse model with an F1L deletion mutant of the HIV/AIDS vaccine candidate MVA-C that expresses Env and Gag-Pol-Nef antigens (MVA-C-ΔF1L). The viral gene F1L is not required for virus replication in cultured cells and its deletion in MVA-C induces extensive apoptosis and expression of immunomodulatory genes in infected cells. Analysis of the immune responses induced in BALB/c mice after DNA prime/MVA boost revealed that, in comparison with parental MVA-C, the mutant MVA-C-ΔF1L improves the magnitude of the HIV-1-specific CD8 T cell adaptive immune responses and impacts on the CD8 T cell memory phase by enhancing the magnitude of the response, reducing the contraction phase and changing the memory differentiation pattern. These findings reveal the immunomodulatory role of F1L and that the loss of this gene is a valid strategy for the optimization of MVA as vaccine vector. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. High Quality Long-Term CD4+ and CD8+ Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection.
- Author
-
Sánchez-Sampedro, Lucas, Gómez, Carmen Elena, Mejías-Pérez, Ernesto, Sorzano, Carlos Oscar S., and Esteban, Mariano
- Subjects
- *
GENETIC vectors , *DNA , *VACCINATION , *RECOMBINANT molecules , *VACCINIA , *LEISHMANIA - Abstract
Heterologous vaccination based on priming with a plasmid DNA vector and boosting with an attenuated vaccinia virus MVA recombinant, with both vectors expressing the Leishmania infantum LACK antigen (DNA-LACK and MVA-LACK), has shown efficacy conferring protection in murine and canine models against cutaneus and visceral leishmaniasis, but the immune parameters of protection remain ill defined. Here we performed by flow cytometry an in depth analysis of the T cell populations induced in BALB/c mice during the vaccination protocol DNA-LACK/MVA-LACK, as well as after challenge with L. major parasites. In the adaptive response, there is a polyfunctional CD4+ and CD8+ T cell activation against LACK antigen. At the memory phase the heterologous vaccination induces high quality LACK-specific long-term CD4+ and CD8+ effector memory cells. After parasite challenge, there is a moderate boosting of LACK-specific CD4+ and CD8+ T cells. Anti-vector responses were largely CD8+-mediated. The immune parameters induced against LACK and triggered by the combined vaccination DNA/MVA protocol, like polyfunctionality of CD4+ and CD8+ T cells with an effector phenotype, could be relevant in protection against leishmaniasis. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. Systems Analysis of MVA-C Induced Immune Response Reveals Its Significance as a Vaccine Candidate against HIV/AIDS of Clade C.
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, Jiménez, Victoria, Filali-Mouhim, Abdelali, Ghneim, Khader, Haddad, Elias K., Quakkerlaar, Esther D., Delaloye, Julie, Harari, Alexandre, Roger, Thierry, Dunhen, Thomas, Sékaly, Rafick P., Melief, Cornelis J. M., Calandra, Thierry, Sallusto, Federica, Lanzavecchia, Antonio, Wagner, Ralf, Pantaleo, Giuseppe, and Esteban, Mariano
- Subjects
- *
LYMPHOCYTES , *IMMUNOGLOBULINS , *VACCINATION , *ANTIGENS , *PREVENTIVE medicine , *IMMUNITY - Abstract
Based on the partial efficacy of the HIV/AIDS Thai trial (RV144) with a canarypox vector prime and protein boost, attenuated poxvirus recombinants expressing HIV-1 antigens are increasingly sought as vaccine candidates against HIV/AIDS. Here we describe using systems analysis the biological and immunological characteristics of the attenuated vaccinia virus Ankara strain expressing the HIV-1 antigens Env/Gag-Pol-Nef of HIV-1 of clade C (referred as MVA-C). MVA-C infection of human monocyte derived dendritic cells (moDCs) induced the expression of HIV-1 antigens at high levels from 2 to 8 hpi and triggered moDCs maturation as revealed by enhanced expression of HLA-DR, CD86, CD40, HLA-A2, and CD80 molecules. Infection ex vivo of purified mDC and pDC with MVA-C induced the expression of immunoregulatory pathways associated with antiviral responses, antigen presentation, T cell and B cell responses. Similarly, human whole blood or primary macrophages infected with MVA-C express high levels of proinflammatory cytokines and chemokines involved with T cell activation. The vector MVA-C has the ability to cross-present antigens to HIV-specific CD8 T cells in vitro and to increase CD8 T cell proliferation in a dose-dependent manner. The immunogenic profiling in mice after DNA-C prime/MVA-C boost combination revealed activation of HIV-1-specific CD4 and CD8 T cell memory responses that are polyfunctional and with effector memory phenotype. Env-specific IgG binding antibodies were also produced in animals receiving DNA-C prime/ MVA-C boost. Our systems analysis of profiling immune response to MVA-C infection highlights the potential benefit of MVA-C as vaccine candidate against HIV/AIDS for clade C, the prevalent subtype virus in the most affected areas of the world. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
24. Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens.
- Author
-
Luis^Nájera, José, Gómez, Carmen Elena, García-Arriaza, Juan, Sorzano, Carlos Oscar, and Esteban, Mariano
- Subjects
- *
HIV , *GENOMES , *IMMUNE response , *ANTIGENS , *CLINICAL trials , *APOPTOSIS , *CELL lines , *T cells , *VACCINIA - Abstract
Background: The highly attenuated vaccinia virus strain NYVAC expressing HIV-1 components has been evaluated as a vaccine candidate in preclinical and clinical trials with encouraging results. We have previously described that the presence of C7L in the NYVAC genome prevents the induction of apoptosis and renders the vector capable of replication in human and murine cell lines while maintaining an attenuated phenotype in mice. Methodology/Principal Findings: In an effort to improve the immunogenicity of NYVAC, we have developed a novel poxvirus vector by inserting the VACV host-range C7L gene into the genome of NYVAC-B, a recombinant virus that expresses four HIV-1 antigens from clade B (Env, Gag, Pol and Nef) (referred as NYVAC-B-C7L). In the present study, we have compared the in vitro and in vivo behavior of NYVAC-B and NYVAC-B-C7L. In cultured cells, NYVAC-B-C7L expresses higher levels of heterologous antigen than NYVAC-B as determined by Western blot and fluorescent-activated cell sorting to score Gag expressing cells. In a DNA prime/poxvirus boost approach with BALB/c mice, both recombinants elicited robust, broad and multifunctional antigen-specific T-cell responses to the HIV-1 immunogens expressed from the vectors. However, the use of NYVAC-B-C7L as booster significantly enhanced the magnitude of the T cell responses, and induced a more balanced cellular immune response to the HIV-1 antigens in comparison to that elicited in animals boosted with NYVAC-B. Conclusions/Significance: These findings demonstrate the possibility to enhance the immunogenicity of the highly attenuated NYVAC vector by the insertion of the host-range gene C7L and suggest the use of this modified vector as an improved vaccine candidate against HIV/AIDS. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
25. Subcellular forms and biochemical events triggered in human cells by HCV polyprotein expression from a viral vector.
- Author
-
Vandermeeren, Andrée M., Gómez, Carmen Elena, Patiño, Cristina, Domingo-Gil, Elena, Guerra, Susana, González, Jose Manuel, and Esteban, Mariano
- Subjects
- *
CELLS , *HEPATITIS C virus , *PATHOLOGY , *VACCINIA , *CELL culture - Abstract
To identify the subcellular forms and biochemical events induced in human cells after HCV polyprotein expression, we have used a robust cell culture system based on vaccinia virus (VACV) that efficiently expresses in infected cells the structural and nonstructural proteins of HCV from genotype 1b (VT7-HCV7.9). As determined by confocal microscopy, HCV proteins expressed from VT7-HCV7.9 localize largely in a globular-like distribution pattern in the cytoplasm, with some proteins co-localizing with the endoplasmic reticulum (ER) and mitochondria. As examined by electron microscopy, HCV proteins induced formation of large electron-dense cytoplasmic structures derived from the ER and containing HCV proteins. In the course of HCV protein production, there is disruption of the Golgi apparatus, loss of spatial organization of the ER, appearance of some "virus-like" structures and swelling of mitochondria. Biochemical analysis demonstrate that HCV proteins bring about the activation of initiator and effector caspases followed by severe apoptosis and mitochondria dysfunction, hallmarks of HCV cell injury. Microarray analysis revealed that HCV polyprotein expression modulated transcription of genes associated with lipid metabolism, oxidative stress, apoptosis, and cellular proliferation. Our findings demonstrate the uniqueness of the VT7-HCV7.9 system to characterize morphological and biochemical events related to HCV pathogenesis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
26. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B
- Author
-
Gómez, Carmen Elena, Nájera, Jose Luis, Jiménez, Eva Pérez, Jiménez, Victoria, Wagner, Ralf, Graf, Marcus, Frachette, Marie-Joelle, Liljeström, Peter, Pantaleo, Giuseppe, and Esteban, Mariano
- Subjects
- *
HIV , *VACCINATION , *POXVIRUS diseases , *IMMUNE response - Abstract
Abstract: In this investigation we have generated and defined the immunogenicity of two novel HIV/AIDS vaccine candidates based on the highly attenuated vaccinia virus strains, MVA and NYVAC, efficiently expressing in the same locus (TK) and under the same viral promoter the codon optimized HIV-1 genes encoding gp120 and Gag-Pol-Nef antigens of clade B (referred as MVA-B and NYVAC-B). In infected human HeLa cells, gp120 is released from cells and GPN is produced as a polyprotein; NYVAC-B induces severe apoptosis but not MVA-B. The two poxvirus vectors showed genetic stability of the inserts. In BALB/c and in transgenic HHD mice for human HLA-A2 class I, both vectors are efficient immunogens and induced broad cellular immune responses against peptides represented in the four HIV-1 antigens. Some differences were observed in the magnitude and breadth of the immune response in the mouse models. In DNA prime/poxvirus boost protocols, the strongest immune response, as measured by fresh IFN-γ and IL-2 ELISPOT, was obtained in BALB/c mice boosted with NYVAC-B, while in HHD mice there were no differences between the poxvirus vectors. When the prime/boost was performed with homologous or with combination of poxvirus vectors, the protocols MVA-B/MVA-B and NYVAC-B/NYVAC-B, or the combination NYVAC-B/MVA-B gave the most consistent broader immune response in both mouse models, although the magnitude of the overall response was higher for the DNA-B/poxvirus-B regime. All of the immunization protocols induced some humoral response against the gp160 protein from HIV-1 clone LAV. Our findings indicate that MVA-B and NYVAC-B meet the criteria to be potentially useful vaccine candidates against HIV/AIDS. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
27. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-γ
- Author
-
Gómez, Carmen Elena, Abaitua, Fernando, Rodríguez, Dolores, and Esteban, Mariano
- Subjects
- *
T cells , *EPITOPES , *GENES , *IMMUNIZATION - Abstract
The cytotoxic T-lymphocyte response (CTL) has been shown to be determinant in the clearance of many viral infections and hence, vaccine candidates against AIDS are designed to enhance this arm of the immune system. In this study, we have analyzed the antigen specific immune responses triggered in mice by different combinations of vaccine vehicles expressing the multiepitope polypeptide TAB13. This chimeric protein contains the V3 region of the gp120 from eight different HIV-1 isolates and was efficiently expressed by a DNA vector (DNA-TAB), and also by vaccinia virus recombinants (rVV) based either on the attenuated modified vaccinia virus Ankara (MVA-TAB) or Western Reserve (VV-TAB) strains. Inoculation of a DNA-TAB vector in priming followed by a booster with VV-TAB or MVA-TAB induces a humoral immune response against TAB13 protein and efficiently enhanced the CD8+ T cell response against V3 epitopes from HIV-1 isolates LR150, MN, and IIIB in comparison with animals immunized with two doses of DNA-TAB. A protocol that incorporates a DNA vector expressing IFN-γ (DNA-IFN-γ) with DNA-TAB in the priming, followed by a booster with MVA-TAB, triggered the highest values of specific CD8+ T cell response. By examining the cytokine pattern, the immune response induced by these vaccination approaches was predominantly of Th-1 type. These findings establish safe strategies for the enhanced generation of T cell mediated immunity to HIV-1 that can benefit in the design of an effective vaccine against AIDS. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
28. Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen.
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, Usero, Lorena, Marcos-Villar, Laura, Miralles, Laia, Leal, Lorna, Sorzano, Carlos Óscar S., Sánchez-Corzo, Cristina, Plana, Montserrat, García, Felipe, and Esteban, Mariano
- Subjects
IMMUNE response ,MESSENGER RNA ,NEGATIVE regulatory factor ,COVID-19 vaccines ,VACCINES - Abstract
Development of a vaccine against HIV remains a major target goal in the field. The recent success of mRNA vaccines against the coronavirus SARS-CoV-2 is pointing out a new era of vaccine designs against pathogens. Here, we have generated two types of mRNA vaccine candidates against HIV-1; one based on unmodified vectors and the other on 1-methyl-3′-pseudouridylyl modified vectors expressing a T cell multiepitopic construct including protective conserved epitopes from HIV-1 Gag, Pol and Nef proteins (referred to as RNA-TMEP and RNA-TMEPmod, respectively) and defined their biological and immunological properties in cultured cells and in mice. In cultured cells, both mRNA vectors expressed the corresponding protein, with higher levels observed in the unmodified mRNA, leading to activated macrophages with differential induction of innate immune molecules. In mice, intranodal administration of the mRNAs induced the activation of specific T cell (CD4 and CD8) responses, and the levels were markedly enhanced after a booster immunization with the poxvirus vector MVA-TMEP expressing the same antigen. This immune activation was maintained even three months later. These findings revealed a potent combined immunization regimen able to enhance the HIV-1-specific immune responses induced by an mRNA vaccine that might be applicable to human vaccination programs with mRNA and MVA vectors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
29. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.
- Author
-
Gómez, Carmen Elena, Perdiguero, Beatriz, Esteban, Mariano, and Bradfute, Steven B.
- Subjects
SARS-CoV-2 ,VIRUS diseases ,VACCINATION ,VIRAL tropism ,HERD immunity ,MONOCLONAL antibodies - Abstract
The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants in different continents is causing a major concern in human global health. These variants have in common a higher transmissibility, becoming dominant within populations in a short time, and an accumulation of a high number of mutations in the spike (S) protein, especially within the amino terminal domain (NTD) and the receptor binding domain (RBD). These mutations have direct implications on virus infection rates through higher affinity of S RBD for the cellular angiotensin-converting enzyme-2 (ACE-2) receptor. There are also signs of enhanced virulence, re-infection frequency, and increased resistance to the action of monoclonal and polyclonal antibodies from convalescence sera and in vaccinated individuals in regions where the variants spread dominantly. In this review, we describe the different SARS-CoV-2 variants that have thus far been identified in various parts of the world with mutational changes and biological properties as well as their impact in medical countermeasures and human health. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
30. Induction of Broad and Polyfunctional HIV-1-Specific T Cell Responses by the Multiepitopic Protein TMEP-B Vectored by MVA Virus.
- Author
-
Perdiguero, Beatriz, Sánchez-Corzo, Cristina, S. Sorzano, Carlos Oscar, Mediavilla, Pilar, Saiz, Lidia, Esteban, Mariano, and Gómez, Carmen Elena
- Subjects
T cells ,IMMUNOLOGICAL deficiency syndromes ,NEGATIVE regulatory factor ,VACCINIA ,DNA vaccines - Abstract
A human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) vaccine able to induce long-lasting immunity remains a major challenge. We previously designed a T cell multiepitopic immunogen including protective conserved epitopes from HIV-1 Gag, Pol and Nef proteins (TMEP-B), that induced potent HIV-1-specific CD8 T cells when vectored by DNA and combined with the vaccine candidate modified vaccinia virus Ankara (MVA)-B. Here, we described the vectorization of TMEP-B in MVA (MVA-TMEP) and evaluated the T cell immunogenicity profile elicited in mice when administered in homologous (MVA/MVA) or heterologous (DNA/MVA) prime/boost vector regimens or using homologous or heterologous inserts. The heterologous vector regimen was superior to the homologous protocol in inducing T cell responses. DNA-TMEP-primed animals boosted with MVA-TMEP or MVA-B exhibited the highest magnitudes of HIV-1-specific CD8, CD4 and T follicular helper (Tfh) cells, with MVA-TMEP significantly expanding Gag-specific CD8 T cell responses. In the homologous vector regimen, all groups exhibited similar HIV-1-specific CD8 and CD4 T cell responses, but both MVA-B/MVA-B and MVA-TMEP/MVA-TMEP combinations elicited higher Gag-Pol-Nef (GPN)-specific CD8 T cell responses compared to MVA-TMEP/MVA-B. Our results revealed an enhanced induction of HIV-1-specific T cell responses by TMEP-B when vectored in both DNA and MVA, and supported their use in combined prime/boost strategies for HIV-1 prevention and/or therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
31. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
- Author
-
Perdiguero, Beatriz, Sánchez-Corzo, Cristina, Sorzano, Carlos Oscar S., Saiz, Lidia, Mediavilla, Pilar, Esteban, Mariano, and Gómez, Carmen Elena
- Subjects
ANTIBODY formation ,AIDS vaccines ,T cells ,VIRUS-like particles ,VACCINIA ,B cells - Abstract
The development of an effective Human Immunodeficiency Virus (HIV) vaccine that is able to stimulate both the humoral and cellular HIV-1-specific immune responses remains a major priority challenge. In this study, we described the generation and preclinical evaluation of single and double modified vaccinia virus Ankara (MVA)-based candidates expressing the HIV-1 clade C membrane-bound gp145(ZM96) trimeric protein and/or the Gag(ZM96)-Pol-Nef(CN54) (GPN) polyprotein that was processed to form Gag-induced virus-like particles (VLPs). In vitro characterization of MVA recombinants revealed the stable integration of HIV-1 genes without affecting its replication capacity. In cells that were infected with Env-expressing viruses, the gp145 protein was inserted into the plasma membrane exposing critical epitopes that were recognized by broadly neutralizing antibodies (bNAbs), whereas Gag-induced VLPs were released from cells that were infected with GPN-expressing viruses. VLP particles as well as purified MVA virions contain Env and Gag visualized by immunoelectron microscopy and western-blot of fractions that were obtained after detergent treatments of purified virus particles. In BALB/c mice, homologous MVA-gp145-GPN prime/boost regimen induced broad and polyfunctional Env- and Gag-specific CD4 T cells and antigen-specific T follicular helper (Tfh) and Germinal Center (GC) B cells, which correlated with robust HIV-1-specific humoral responses. Overall, these results support the consideration of MVA-gp145-GPN vector as a potential vaccine candidate against HIV-1. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
32. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
- Author
-
Perdiguero, Beatriz, Raman, Suresh C., Sánchez-Corzo, Cristina, Esteban, Mariano, Gómez, Carmen Elena, S. Sorzano, Carlos Oscar, and Valverde, José Ramón
- Subjects
T cells ,HIV infections ,VACCINATION ,IMMUNOGENETICS ,PROTEINS - Abstract
An effective vaccine against Human Immunodeficiency Virus (HIV) still remains the best solution to provide a sustainable control and/or eradication of the virus. We have previously generated the HIV-1 vaccine modified vaccinia virus Ankara (MVA)-B, which exhibited good immunogenicity profile in phase I prophylactic and therapeutic clinical trials, but was unable to prevent viral rebound after antiretroviral (ART) removal. To potentiate the immunogenicity of MVA-B, here we described the design and immune responses elicited in mice by a new T cell multi-epitopic B (TMEP-B) immunogen, vectored by DNA, when administered in homologous or heterologous prime/boost regimens in combination with MVA-B. The TMEP-B protein contained conserved regions from Gag, Pol, and Nef proteins including multiple CD4 and CD8 T cell epitopes functionally associated with HIV control. Heterologous DNA-TMEP/MVA-B regimen induced higher HIV-1-specific CD8 T cell responses with broader epitope recognition and higher polyfunctional profile than the homologous DNA-TMEP/DNA-TMEP or the heterologous DNA-GPN/MVA-B combinations. Moreover, higher HIV-1-specific CD4 and Tfh immune responses were also detected using this regimen. After MVA-B boost, the magnitude of the anti-VACV CD8 T cell response was significantly compromised in DNA-TMEP-primed animals. Our results revealed the immunological potential of DNA-TMEP prime/MVA-B boost regimen and supported the application of these combined vectors in HIV-1 prevention and/or therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
33. Correction: Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Author
-
Guardo, Alberto C., Gómez, Carmen Elena, Díaz-Brito, Vicens, Pich, Judit, Arnaiz, Joan Albert, Perdiguero, Beatriz, García-Arriaza, Juan, González, Nuria, Sorzano, Carlos O. S., Jiménez, Laura, Jiménez, José Luis, Muñoz-Fernández, María Ángeles, Gatell, José M, Alcamí, José, Esteban, Mariano, de Quirós, Juan Carlos López Bernaldo, García, Felipe, and Plana, Montserrat
- Subjects
- *
PERIODICAL articles , *HIV infections - Published
- 2018
- Full Text
- View/download PDF
34. Bivalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs.
- Author
-
Gómez, Carmen Elena, Cepeda, María Victoria, Sánchez-Sampedro, Lucas, García-Arriaza, Juan, Mejías-Pérez, Ernesto, Jiménez, Victoria, Sánchez, Cristina, Sorzano, Carlos Oscar S., Delaloye, Julie, Roger, Thierry, Calandra, Thierry, Wagner, Ralf, Asbach, Benedikt, Kibler, Karen V., Jacobs, Bertram L, Pantaleo, Giuseppe, and Esteban, Mariano
- Abstract
An abstract of the article "Bivalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs" by Benedikt Asbach, Mariano Esteban and Karen V. Kibler and colleagues is presented.
- Published
- 2014
- Full Text
- View/download PDF
35. Vaccinia Virus with Selective Deletions Enhances T Cell Response to HIV Antigens by Specific Neutrophil Recruitment.
- Author
-
Mejías-Pérez, Ernesto, Zonca, Manuela, Perdiguero, Beatriz, Gómez, Carmen Elena, Trakala, Marianna, Nieto, Jacobo, Nájera, José Luis, Sorzano, Carlos Oscar S., Planelles, Lourdes, and Esteban, Mariano
- Abstract
An abstract of the article "Vaccinia Virus with Selective Deletions Enhances T Cell Response to HIV Antigens by Specific Neutrophil Recruitment" by Mauro Di Pilato, Ernesto Mejías-Peérez, Manuela Zonca and colleagues is presented.
- Published
- 2014
- Full Text
- View/download PDF
36. Deletion of the Vaccinia Virus Gene A46R, Encoding for an Inhibitor of TLR Signalling, Is an Effective Approach to Enhance the Immunogenicity in Mice of the HIV/AIDS Vaccine Candidate NYVAC-C.
- Author
-
Perdiguero, Beatriz, Gómez, Carmen Elena, Di Pilato, Mauro, Sorzano, Carlos Oscar S., Delaloye, Julie, Roger, Thierry, Calandra, Thierry, Pantaleo, Giuseppe, and Esteban, Mariano
- Subjects
- *
VACCINIA , *GENETIC code , *AIDS vaccines , *TOLL-like receptors , *CYTOKINES , *IMMUNE response , *LABORATORY mice - Abstract
Viruses have developed strategies to counteract signalling through Toll-like receptors (TLRs) that are involved in the detection of viruses and induction of proinflammatory cytokines and IFNs. Vaccinia virus (VACV) encodes A46 protein which disrupts TLR signalling by interfering with TLR: adaptor interactions. Since the innate immune response to viruses is critical to induce protective immunity, we studied whether deletion of A46R gene in a NYVAC vector expressing HIV-1 Env, Gag, Pol and Nef antigens (NYVAC-C) improves immune responses against HIV-1 antigens. This question was examined in human macrophages and in mice infected with a single A46R deletion mutant of the vaccine candidate NYVAC-C (NYVAC-C-ΔA46R). The viral gene A46R is not required for virus replication in primary chicken embryo fibroblast (CEF) cells and its deletion in NYVAC-C markedly increases TNF, IL-6 and IL-8 secretion by human macrophages. Analysis of the immune responses elicited in BALB/c mice after DNA prime/NYVAC boost immunization shows that deletion of A46R improves the magnitude of the HIV-1-specific CD4 and CD8 T cell immune responses during adaptive and memory phases, maintains the functional profile observed with the parental NYVAC-C and enhances anti-gp120 humoral response during the memory phase. These findings establish the immunological role of VACV A46R on innate immune responses of macrophages in vitro and antigen-specific T and B cell immune responses in vivo and suggest that deletion of viral inhibitors of TLR signalling is a useful approach for the improvement of poxvirus-based vaccine candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
37. Cellular and Biochemical Differences between Two Attenuated Poxvirus Vaccine Candidates (MVA and NYVAC) and Role of the C7L Gene.
- Author
-
Nájera, José Luis, Gómez, Carmen Elena, Domingo-Gil, Elena, Magdalena Gherardi, María, and Esteban, Mariano
- Subjects
- *
POXVIRUSES , *DNA viruses , *VACCINES , *CELLS , *CELL lines , *ELECTRON microscopy - Abstract
The poxvirus strains NYVAC and MVA are two candidate vectors for the development of vaccines against a broad spectrum of diseases. Although these attenuated virus strains have proven to be safe in animals and humans, little is known about their comparative behavior in vitro. In contrast with MVA, NYVAC infection triggers greater cytopathic effect in a range of permissive and nonpermissive cell lines. The yields of NYVAC cell-associated virus in permissive cells (BHK-21) were slightly reduced compared with those of MVA infection. During the course of infection in HeLa cells, there is a translational block induced by NYVAC late in infection, which correlated with a marked increase in phosphorylation levels of the initiation factor eIF-2α. In contrast to MVA, the synthesis of certain late viral proteins was only blocked in NYVAC-infected HeLa cells. Electron microscopy (EM) analysis revealed that morphogenesis of NYVAC in HeLa cells was blocked at the stage of formation of immature viral forms. Phase-contrast microscopy, EM, flow cytometry, and rRNA analyses demonstrated that contrary to MVA, NYVAC infection induces potent apoptosis, a phenomenon dependent on activation of caspases and RNase L. Apoptosis induced by NYVAC was prevented when the virus gene C7L was placed back into the NYVAC genome, recovering the ability of NYVAC to replicate in HeLa cells and maintaining the attenuated phenotype in mice. Overall, our findings demonstrate distinct behavior between NYVAC and MVA strains in cultured cells, as well as a new role for the C7L viral gene as an inhibitor of apoptosis in NYVAC infection. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
38. Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium.
- Author
-
Marcos-Villar L, Perdiguero B, López-Bravo M, Zamora C, Sin L, Álvarez E, Sorzano CÓS, Sánchez-Cordón PJ, Casasnovas JM, Astorgano D, García-Arriaza J, Anthiya S, Borrajo ML, Lou G, Cuesta B, Franceschini L, Gelpí JL, Thielemans K, Sisteré-Oró M, Meyerhans A, García F, Esteban I, López-Bigas N, Plana M, Alonso MJ, Esteban M, and Gómez CE
- Subjects
- Animals, Mice, Humans, Female, Nanoparticles administration & dosage, Vaccination, mRNA Vaccines administration & dosage, Mice, Transgenic, Vaccines, Synthetic immunology, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic genetics, CD8-Positive T-Lymphocytes immunology, Angiotensin-Converting Enzyme 2 immunology, Angiotensin-Converting Enzyme 2 genetics, Liposomes, COVID-19 Vaccines immunology, COVID-19 Vaccines administration & dosage, SARS-CoV-2 immunology, SARS-CoV-2 genetics, Spike Glycoprotein, Coronavirus immunology, Spike Glycoprotein, Coronavirus genetics, COVID-19 prevention & control, COVID-19 immunology, Antibodies, Viral immunology, Antibodies, Viral blood, Antibodies, Neutralizing immunology, Mice, Inbred C57BL, Vaccinia virus genetics, Vaccinia virus immunology
- Abstract
Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) against both the ancestral SARS-CoV-2 strain and different variants of concern (VoCs). Additionally, this protocol induced robust and polyfunctional RBD-specific CD4 and CD8 T cell responses, particularly in animals primed with mLNP-RBD. In K18-hACE2 transgenic mice, the LNP-RBD/MVA combination provided complete protection from morbidity and mortality following a live SARS-CoV-2 challenge compared with the partial protection observed with mNE-RBD/MVA or MVA/MVA regimens. Although the mNE-RBD/MVA regimen only protects half of the animals, it was able to induce antibodies with Fc-mediated effector functions besides NAbs. Moreover, viral replication and viral load in the respiratory tract were markedly reduced and decreased pro-inflammatory cytokine levels were observed. These results support the efficacy of heterologous mRNA/MVA vaccine combinations over homologous MVA/MVA regimen, using alternative nanocarriers that circumvent intellectual property restrictions of current mRNA vaccine formulations.
- Published
- 2024
- Full Text
- View/download PDF
39. Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA).
- Author
-
Esteban I, Pastor-Quiñones C, Usero L, Aurrecoechea E, Franceschini L, Esprit A, Gelpí JL, Martínez-Jiménez F, López-Bigas N, Breckpot K, Thielemans K, Leal L, Gómez CE, Sisteré-Oró M, Meyerhans A, Esteban M, Alonso MJ, García F, and Plana M
- Abstract
The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we present two new mRNAs expressing antigenic parts of the SARS-CoV-2 spike protein and provide data supporting their functionality. The first mRNA, called RBD-mRNA, encodes a trimeric form of the virus spike protein receptor binding domain (RBD). The other mRNA, termed T-mRNA, codes for the relevant HLA I and II spike epitopes. The two mRNAs (COVARNA mRNAs) were designed to be used for delivery to cells in combination, with the RBD-mRNA being the primary source of antigen and the T-mRNA working as an enhancer of immunogenicity by supporting CD4 and CD8 T-cell activation. This innovative approach substantially differs from other available mRNA vaccines, which are largely directed to antibody production by the entire spike protein. In this study, we first show that both mRNAs are functionally transfected into human antigen-presenting cells (APCs). We obtained peripheral blood mononuclear cell (PBMC) samples from three groups of voluntary donors differing in their immunity against SARS-CoV-2: non-infected (naïve), infected-recovered (convalescent), and vaccinated. Using an established method of co-culturing autologous human dendritic cells (hDCs) with T-cells, we detected proliferation and cytokine secretion, thus demonstrating the ability of the COVARNA mRNAs to activate T-cells in an antigen-specific way. Interestingly, important differences in the intensity of the response between the infected-recovered (convalescent) and vaccinated donors were observed, with the levels of T-cell proliferation and cytokine secretion (IFNγ, IL-2R, and IL-13) being higher in the vaccinated group. In summary, our data support the further study of these mRNAs as a combined approach for future use as a vaccine.
- Published
- 2023
- Full Text
- View/download PDF
40. Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein.
- Author
-
Perdiguero B, Hauser A, Gómez CE, Peterhoff D, Sideris E, Sorzano CÓS, Wilmschen S, Schaber M, Stengel L, Asbach B, Ding S, Von Laer D, Levy Y, Pantaleo G, Kimpel J, Esteban M, and Wagner R
- Subjects
- Animals, Mice, HIV Antibodies, Membrane Proteins, env Gene Products, Human Immunodeficiency Virus genetics, Antibodies, Neutralizing, Immunity, HIV-1 genetics, HIV Seropositivity, AIDS Vaccines genetics
- Abstract
Introduction: The generation of an HIV-1 vaccine able to induce long-lasting protective immunity remains a main challenge. Here, we aimed to modify next-generation soluble, prefusion-stabilized, close-to-native, glycan-engineered clade C gp140 envelope (Env) trimers (sC23v4 KIKO and ConCv5 KIKO) for optimal display on the cell surface following homologous or heterologous vector delivery., Methods: A combination of the following modifications scored best regarding the preservation of closed, native-like Env trimer conformation and antigenicity when using a panel of selected broadly neutralizing (bnAb) and non-neutralizing (nnAb) monoclonal antibodies for flow cytometry: i) replacing the natural cleavage site with a native flexible linker and introducing a single amino acid substitution to prevent CD4 binding (*), ii) fusing a heterologous VSV-G-derived transmembrane moiety to the gp140 C-terminus, and iii) deleting six residues proximal to the membrane., Results: When delivering membrane-tethered sC23v4 KIKO* and ConCv5 KIKO* via DNA, VSV-GP, and NYVAC vectors, the two native-like Env trimers provide differential antigenicity profiles. Whereas such patterns were largely consistent among the different vectors for either Env trimer, the membrane-tethered ConCv5 KIKO* trimer adopted a more closed and native-like structure than sC23v4 KIKO*. In immunized mice, VSV-GP and NYVAC vectors expressing the membrane-tethered ConCv5 KIKO* administered in prime/boost combination were the most effective regimens for the priming of Env-specific CD4 T cells among all tested combinations. The subsequent booster administration of trimeric ConCv5 KIKO* Env protein preserved the T cell activation levels between groups. The evaluation of the HIV-1-specific humoral responses induced in the different immunization groups after protein boosts showed that the various prime/boost protocols elicited broad and potent antibody responses, preferentially of a Th1-associated IgG2a subclass, and that the obtained antibody levels remained high at the memory phase., Discussion: In summary, we provide a feasible strategy to display multiple copies of native-like Env trimers on the cell surface, which translates into efficient priming of sustained CD4
+ T cell responses after vector delivery as well as broad, potent, and sustained antibody responses following booster immunizations with the homologous, prefusion-stabilized, close-to-native ConCv5 KIKO* gp140 Env trimer., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision., (Copyright © 2023 Perdiguero, Hauser, Gómez, Peterhoff, Sideris, Sorzano, Wilmschen, Schaber, Stengel, Asbach, Ding, Von Laer, Levy, Pantaleo, Kimpel, Esteban and Wagner.)- Published
- 2023
- Full Text
- View/download PDF
41. An MVA-based vector expressing cell-free ISG15 increases IFN-I production and improves HIV-1-specific CD8 T cell immune responses.
- Author
-
Falqui M, Perdiguero B, Coloma R, Albert M, Marcos-Villar L, McGrail JP, Sorzano CÓS, Esteban M, Gómez CE, and Guerra S
- Subjects
- Humans, Animals, Mice, Vaccinia virus genetics, Adjuvants, Immunologic, CD8-Positive T-Lymphocytes, Immunity, Ubiquitins genetics, Cytokines, HIV-1 genetics, Interferon Type I
- Abstract
The human immunodeficiency virus (HIV), responsible of the Acquired Immune Deficiency Syndrome (AIDS), continues to be a major global public health issue with any cure or vaccine available. The Interferon-stimulated gene 15 (ISG15) encodes a ubiquitin-like protein that is induced by interferons and plays a critical role in the immune response. ISG15 is a modifier protein that covalently binds to its targets via a reversible bond, a process known as ISGylation, which is the best-characterized activity of this protein to date. However, ISG15 can also interact with intracellular proteins via non-covalent binding or act as a cytokine in the extracellular space after secretion. In previous studies we proved the adjuvant effect of ISG15 when delivered by a DNA-vector in heterologous prime-boost combination with a Modified Vaccinia virus Ankara (MVA)-based recombinant virus expressing HIV-1 antigens Env/Gag-Pol-Nef (MVA-B). Here we extended these results evaluating the adjuvant effect of ISG15 when expressed by an MVA vector. For this, we generated and characterized two novel MVA recombinants expressing different forms of ISG15, the wild-type ISG15GG (able to perform ISGylation) or the mutated ISG15AA (unable to perform ISGylation). In mice immunized with the heterologous DNA prime/MVA boost regimen, the expression of the mutant ISG15AA from MVA-Δ3-ISG15AA vector in combination with MVA-B induced an increase in the magnitude and quality of HIV-1-specific CD8 T cells as well as in the levels of IFN-I released, providing a better immunostimulatory activity than the wild-type ISG15GG. Our results confirm the importance of ISG15 as an immune adjuvant in the vaccine field and highlights its role as a potential relevant component in HIV-1 immunization protocols., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Falqui, Perdiguero, Coloma, Albert, Marcos-Villar, McGrail, Sorzano, Esteban, Gómez and Guerra.)
- Published
- 2023
- Full Text
- View/download PDF
42. Enhancement of HIV-1 Env-Specific CD8 T Cell Responses Using Interferon-Stimulated Gene 15 as an Immune Adjuvant.
- Author
-
Gómez CE, Perdiguero B, Falqui M, Marín MQ, Bécares M, Sorzano CÓS, García-Arriaza J, Esteban M, and Guerra S
- Subjects
- AIDS Vaccines administration & dosage, Animals, Cytokines administration & dosage, Cytokines genetics, Female, HEK293 Cells, HIV Antibodies immunology, HIV Envelope Protein gp120 administration & dosage, HIV Envelope Protein gp120 genetics, Humans, Immunization, Secondary, Immunologic Memory, Immunomodulation, Mice, Mice, Inbred BALB C, Mutation, Ubiquitins administration & dosage, Ubiquitins genetics, Ubiquitins immunology, Vaccine Potency, Vaccines, Synthetic administration & dosage, Vaccines, Synthetic immunology, Vaccinia virus genetics, AIDS Vaccines immunology, Adjuvants, Immunologic administration & dosage, Adjuvants, Immunologic genetics, CD8-Positive T-Lymphocytes immunology, Cytokines immunology, HIV Envelope Protein gp120 immunology, HIV-1 immunology, Immunization methods
- Abstract
Induction of the endogenous innate immune system by interferon (IFN) triggers the expression of many proteins that serve like alarm bells in the body, activating an immune response. After a viral infection, one of the genes activated by IFN induction is the IFN-stimulated gene 15 ( ISG15 ), which encodes a ubiquitin-like protein that undergoes a reversible posttranslational modification (ISGylation). ISG15 protein can also act unconjugated, intracellularly and secreted, acting as a cytokine. Although ISG15 has an essential role in host defense responses to microbial infection, its role as an immunomodulator in the vaccine field remains to be defined. In this investigation, we showed that ISG15 exerts an immunomodulatory role in human immunodeficiency virus (HIV) vaccines. In mice, after priming with a DNA-ISG15 vector mixed with a DNA expressing HIV-1 gp120 (DNA-gp120), followed by a booster with a modified vaccinia virus Ankara (MVA) vector expressing HIV-1 antigens, both wild-type ISG15-conjugated (ISG15-wt) and mutant unconjugated (ISG15-mut) proteins act as immune adjuvants by increasing the magnitude and quality of HIV-1-specific CD8 T cells, with ISG15-wt providing better immunostimulatory activity than ISG15-mut. The HIV-1 Env-specific CD8 T cell responses showed a predominant T effector memory (TEM) phenotype in all groups. Moreover, the amount of DNA-gp120 used to immunize mice could be reduced 5-fold after mixing with DNA-ISG15 without affecting the potency and the quality of the HIV-1 Env-specific immune responses. Our study clearly highlights the potential use of the IFN-induced ISG15 protein as immune adjuvant to enhance immune responses to HIV antigens, suggesting that this molecule might be exploitable for prophylactic and therapeutic vaccine approaches against pathogens. IMPORTANCE Our study described the potential role of ISG15 as an immunomodulatory molecule in the optimization of HIV/AIDS vaccine candidates. Using a DNA prime-MVA boost immunization protocol, our results indicated an increase in the potency and the quality of the HIV-1 Env-specific CD8 T cell response. These results highlight the adjuvant potency of ISG15 to elicit improved viral antigen presentation to the immune system, resulting in an enhanced HIV-1 vaccine immune response. The DNA-ISG15 vector could find applicability in the vaccine field in combination with other nucleic acid-based vector vaccines., (Copyright © 2020 American Society for Microbiology.)
- Published
- 2020
- Full Text
- View/download PDF
43. Bioluminescence Imaging as a Tool for Poxvirus Biology.
- Author
-
Perdiguero B, Gómez CE, and Esteban M
- Subjects
- Animals, Antiviral Agents pharmacology, Humans, Poxviridae genetics, Virus Diseases prevention & control, Luminescent Measurements methods, Poxviridae drug effects
- Abstract
Bioluminescence imaging, with luciferase as a reporter-encoding gene, has been successfully and widely used for studies to follow viral infection in an organism and to measure therapeutic efficacy of antiviral agents in small animal models. Bioluminescence is produced by the reaction of a luciferase enzyme stably inserted into the viral genome with a defined substrate systemically delivered into the animal. The light emitted is captured allowing the detection of viral infection sites and the quantification of viral replication in the context of tissues of a living animal. The goal of this chapter is to provide a technical background for the evaluation of poxvirus infection in cells and animals through bioluminescence imaging technology using luciferase-expressing recombinant poxviruses.
- Published
- 2019
- Full Text
- View/download PDF
44. Immune Modulation of NYVAC-Based HIV Vaccines by Combined Deletion of Viral Genes that Act on Several Signalling Pathways.
- Author
-
Gómez CE, Perdiguero B, Sánchez-Corzo C, Sorzano COS, and Esteban M
- Subjects
- Animals, Cells, Cultured, Chick Embryo, Cytokines antagonists & inhibitors, Cytokines metabolism, Female, Genetic Vectors genetics, HIV Antibodies blood, HIV Antigens immunology, HIV Envelope Protein gp120 immunology, HIV Infections immunology, HIV Infections prevention & control, HIV-1 immunology, Mice, Mice, Inbred BALB C, Sequence Deletion, Toll-Like Receptors antagonists & inhibitors, Toll-Like Receptors metabolism, AIDS Vaccines genetics, AIDS Vaccines immunology, HIV-1 genetics, Signal Transduction immunology, Vaccinia virus genetics, Viral Proteins genetics
- Abstract
An HIV-1 vaccine continues to be a major target to halt the AIDS pandemic. The limited efficacy of the RV144 phase III clinical trial with the canarypox virus-based vector ALVAC and a gp120 protein component led to the conclusion that improved immune responses to HIV antigens are needed for a more effective vaccine. In non-human primates, the New York vaccinia virus (NYVAC) poxvirus vector has a broader immunogenicity profile than ALVAC and has been tested in clinical trials. We therefore analysed the HIV immune advantage of NYVAC after removing viral genes that act on several signalling pathways (Toll-like receptors-TLR-interferon, cytokines/chemokines), as well as genes of unknown immune function. We generated a series of NYVAC deletion mutants and studied immune behaviour (T and B cell) to HIV antigens and to the NYVAC vector in mice. Our results showed that combined deletion of selected vaccinia virus (VACV) genes is a valuable strategy for improving the immunogenicity of NYVAC-based vaccine candidates. These immune responses were differentially modulated, positive or negative, depending on the combination of gene deletions. The deletions also led to enhanced antigen- or vector-specific cellular and humoral responses. These findings will facilitate the development of optimal NYVAC-based vaccines for HIV and other diseases., Competing Interests: The authors declare no conflict of interest.
- Published
- 2017
- Full Text
- View/download PDF
45. Safety and vaccine-induced HIV-1 immune responses in healthy volunteers following a late MVA-B boost 4 years after the last immunization.
- Author
-
Guardo AC, Gómez CE, Díaz-Brito V, Pich J, Arnaiz JA, Perdiguero B, García-Arriaza J, González N, Sorzano COS, Jiménez L, Jiménez JL, Muñoz-Fernández MÁ, Gatell JM, Alcamí J, Esteban M, López Bernaldo de Quirós JC, García F, and Plana M
- Subjects
- AIDS Vaccines adverse effects, Antibodies, Neutralizing immunology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, HIV Antibodies blood, Healthy Volunteers, Humans, Placebos, AIDS Vaccines immunology, HIV-1 immunology, Immunization, Secondary
- Abstract
Background: We have previously shown that an HIV vaccine regimen including three doses of HIV-modified vaccinia virus Ankara vector expressing HIV-1 antigens from clade B (MVA-B) was safe and elicited moderate and durable (1 year) T-cell and antibody responses in 75% and 95% of HIV-negative volunteers (n = 24), respectively (RISVAC02 study). Here, we describe the long-term durability of vaccine-induced responses and the safety and immunogenicity of an additional MVA-B boost., Methods: 13 volunteers from the RISVAC02 trial were recruited to receive a fourth dose of MVA-B 4 years after the last immunization. End-points were safety, cellular and humoral immune responses to HIV-1 and vector antigens assessed by ELISPOT, intracellular cytokine staining (ICS) and ELISA performed before and 2, 4 and 12 weeks after receiving the boost., Results: Volunteers reported 64 adverse events (AEs), although none was a vaccine-related serious AE. After 4 years from the 1st dose of the vaccine, only 2 volunteers maintained low HIV-specific T-cell responses. After the late MVA-B boost, a modest increase in IFN-γ T-cell responses, mainly directed against Env, was detected by ELISPOT in 5/13 (38%) volunteers. ICS confirmed similar results with 45% of volunteers showing that CD4+ T-cell responses were mainly directed against Env, whereas CD8+ T cell-responses were similarly distributed against Env, Gag and GPN. In terms of antibody responses, 23.1% of the vaccinees had detectable Env-specific binding antibodies 4 years after the last MVA-B immunization with a mean titer of 96.5. The late MVA-B boost significantly improved both the response rate (92.3%) and the magnitude of the systemic binding antibodies to gp120 (mean titer of 11460). HIV-1 neutralizing antibodies were also enhanced and detected in 77% of volunteers. Moreover, MVA vector-specific T cell and antibody responses were boosted in 80% and 100% of volunteers respectively., Conclusions: One boost of MVA-B four years after receiving 3 doses of the same vaccine was safe, induced moderate increases in HIV-specific T cell responses in 38% of volunteers but significantly boosted the binding and neutralizing antibody responses to HIV-1 and to the MVA vector., Trial Registration: ClinicalTrials.gov NCT01923610.
- Published
- 2017
- Full Text
- View/download PDF
46. Virological and immunological characterization of novel NYVAC-based HIV/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles.
- Author
-
Perdiguero B, Gómez CE, Cepeda V, Sánchez-Sampedro L, García-Arriaza J, Mejías-Pérez E, Jiménez V, Sánchez C, Sorzano CÓ, Oliveros JC, Delaloye J, Roger T, Calandra T, Asbach B, Wagner R, Kibler KV, Jacobs BL, Pantaleo G, and Esteban M
- Subjects
- AIDS Vaccines administration & dosage, AIDS Vaccines genetics, Animals, CD8-Positive T-Lymphocytes immunology, Cells, Cultured, Chickens, HIV Antibodies blood, Mice, Microscopy, Electron, Transmission, Vaccines, Virus-Like Particle administration & dosage, Vaccines, Virus-Like Particle genetics, Vaccines, Virus-Like Particle ultrastructure, env Gene Products, Human Immunodeficiency Virus genetics, gag Gene Products, Human Immunodeficiency Virus genetics, nef Gene Products, Human Immunodeficiency Virus genetics, AIDS Vaccines immunology, Vaccination methods, Vaccines, Virus-Like Particle immunology, env Gene Products, Human Immunodeficiency Virus immunology, gag Gene Products, Human Immunodeficiency Virus immunology, nef Gene Products, Human Immunodeficiency Virus immunology
- Abstract
Unlabelled: The generation of vaccines against HIV/AIDS able to induce long-lasting protective immunity remains a major goal in the HIV field. The modest efficacy (31.2%) against HIV infection observed in the RV144 phase III clinical trial highlighted the need for further improvement of HIV vaccine candidates, formulation, and vaccine regimen. In this study, we have generated two novel NYVAC vectors, expressing HIV-1 clade C gp140(ZM96) (NYVAC-gp140) or Gag(ZM96)-Pol-Nef(CN54) (NYVAC-Gag-Pol-Nef), and defined their virological and immunological characteristics in cultured cells and in mice. The insertion of HIV genes does not affect the replication capacity of NYVAC recombinants in primary chicken embryo fibroblast cells, HIV sequences remain stable after multiple passages, and HIV antigens are correctly expressed and released from cells, with Env as a trimer (NYVAC-gp140), while in NYVAC-Gag-Pol-Nef-infected cells Gag-induced virus-like particles (VLPs) are abundant. Electron microscopy revealed that VLPs accumulated with time at the cell surface, with no interference with NYVAC morphogenesis. Both vectors trigger specific innate responses in human cells and show an attenuation profile in immunocompromised adult BALB/c and newborn CD1 mice after intracranial inoculation. Analysis of the immune responses elicited in mice after homologous NYVAC prime/NYVAC boost immunization shows that recombinant viruses induced polyfunctional Env-specific CD4 or Gag-specific CD8 T cell responses. Antibody responses against gp140 and p17/p24 were elicited. Our findings showed important insights into virus-host cell interactions of NYVAC vectors expressing HIV antigens, with the activation of specific immune parameters which will help to unravel potential correlates of protection against HIV in human clinical trials with these vectors., Importance: We have generated two novel NYVAC-based HIV vaccine candidates expressing HIV-1 clade C trimeric soluble gp140 (ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs. These vectors are stable and express high levels of both HIV-1 antigens. Gag-induced VLPs do not interfere with NYVAC morphogenesis, are highly attenuated in immunocompromised and newborn mice after intracranial inoculation, trigger specific innate immune responses in human cells, and activate T (Env-specific CD4 and Gag-specific CD8) and B cell immune responses to the HIV antigens, leading to high antibody titers against gp140. For these reasons, these vectors can be considered vaccine candidates against HIV/AIDS and currently are being tested in macaques and humans., (Copyright © 2015, American Society for Microbiology. All Rights Reserved.)
- Published
- 2015
- Full Text
- View/download PDF
47. New vaccinia virus promoter as a potential candidate for future vaccines.
- Author
-
Di Pilato M, Mejías-Pérez E, Gómez CE, Perdiguero B, Sorzano COS, and Esteban M
- Subjects
- Animals, Base Sequence, CD8-Positive T-Lymphocytes metabolism, Cytokines metabolism, Green Fluorescent Proteins genetics, Mice, Vaccinia prevention & control, Vaccinia virus immunology, Vaccinia virus physiology, CD8-Positive T-Lymphocytes immunology, Drug Design, Green Fluorescent Proteins immunology, Promoter Regions, Genetic genetics, Vaccinia immunology, Vaccinia virus genetics, Viral Vaccines genetics
- Abstract
Here we describe the design and strength of a new synthetic late-early optimized (LEO) vaccinia virus (VACV) promoter used as a transcriptional regulator of GFP expression during modified vaccinia Ankara infection. In contrast to the described synthetic VACV promoter (pS), LEO induced significantly higher levels of GFP expression in vitro within the first hour after infection, which correlated with an enhancement in the GFP-specific CD8 T-cell response detected in vivo, demonstrating its potential use in future vaccines.
- Published
- 2013
- Full Text
- View/download PDF
48. Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C.
- Author
-
Perdiguero B, Gómez CE, Di Pilato M, Sorzano CO, Delaloye J, Roger T, Calandra T, Pantaleo G, and Esteban M
- Subjects
- Adaptive Immunity, Animals, HIV Envelope Protein gp120 immunology, HIV Infections prevention & control, HIV-1 immunology, Humans, Immunity, Humoral, Immunologic Memory, Interleukin-6 biosynthesis, Interleukin-8 biosynthesis, Macrophages immunology, Macrophages metabolism, Mice, Mutation, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Tumor Necrosis Factors biosynthesis, AIDS Vaccines genetics, AIDS Vaccines immunology, Gene Deletion, Signal Transduction, Toll-Like Receptors metabolism, Vaccinia virus genetics, Viral Proteins genetics
- Abstract
Viruses have developed strategies to counteract signalling through Toll-like receptors (TLRs) that are involved in the detection of viruses and induction of proinflammatory cytokines and IFNs. Vaccinia virus (VACV) encodes A46 protein which disrupts TLR signalling by interfering with TLR: adaptor interactions. Since the innate immune response to viruses is critical to induce protective immunity, we studied whether deletion of A46R gene in a NYVAC vector expressing HIV-1 Env, Gag, Pol and Nef antigens (NYVAC-C) improves immune responses against HIV-1 antigens. This question was examined in human macrophages and in mice infected with a single A46R deletion mutant of the vaccine candidate NYVAC-C (NYVAC-C-ΔA46R). The viral gene A46R is not required for virus replication in primary chicken embryo fibroblast (CEF) cells and its deletion in NYVAC-C markedly increases TNF, IL-6 and IL-8 secretion by human macrophages. Analysis of the immune responses elicited in BALB/c mice after DNA prime/NYVAC boost immunization shows that deletion of A46R improves the magnitude of the HIV-1-specific CD4 and CD8 T cell immune responses during adaptive and memory phases, maintains the functional profile observed with the parental NYVAC-C and enhances anti-gp120 humoral response during the memory phase. These findings establish the immunological role of VACV A46R on innate immune responses of macrophages in vitro and antigen-specific T and B cell immune responses in vivo and suggest that deletion of viral inhibitors of TLR signalling is a useful approach for the improvement of poxvirus-based vaccine candidates.
- Published
- 2013
- Full Text
- View/download PDF
49. Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice.
- Author
-
Gómez CE, Perdiguero B, Nájera JL, Sorzano CO, Jiménez V, González-Sanz R, and Esteban M
- Subjects
- AIDS Vaccines genetics, Animals, CD8-Positive T-Lymphocytes immunology, Chick Embryo, Gene Deletion, Genetic Vectors immunology, HIV Envelope Protein gp120 genetics, HIV Envelope Protein gp120 immunology, HIV Infections immunology, HIV Infections prevention & control, HIV-1 genetics, HIV-1 immunology, Haplorhini, Mice, Mice, Inbred BALB C, Signal Transduction immunology, T-Lymphocytes immunology, Vaccinia virus genetics, Vaccinia virus immunology, AIDS Vaccines immunology, Adaptive Immunity, Immunologic Memory, Interferon Type I metabolism, Interferon-gamma metabolism
- Abstract
Poxviruses encode multiple inhibitors of the interferon (IFN) system, acting at different levels and blocking the induction of host defense mechanisms. Two viral gene products, B19 and B8, have been shown to act as decoy receptors of type I and type II IFNs, blocking the binding of IFN to its receptor. Since IFN plays a major role in innate immune responses, in this investigation we asked to what extent the viral inhibitors of the IFN system impact the capacity of poxvirus vectors to activate immune responses. This was tested in a mouse model with single and double deletion mutants of the vaccine candidate NYVAC-C, which expresses the HIV-1 Env, Gag, Pol, and Nef antigens. When deleted individually or in double, the type I (B19) and type II (B8) IFN binding proteins were not required for virus replication in cultured cells. Studies of immune responses in mice after DNA prime/NYVAC boost revealed that deletion of B8R and/or B19R genes improved the magnitude and quality of HIV-1-specific CD8(+) T cell adaptive immune responses and impacted their memory phase, changing the contraction, the memory differentiation, the effect magnitude, and the functionality profile. For B cell responses, deletion of the viral gene B8R and/or B19R had no effect on antibody levels to HIV-1 Env. These findings revealed that single or double deletion of viral factors (B8 and B19) targeting the IFN pathway is a useful approach in the design of improved poxvirus-based vaccines.
- Published
- 2012
- Full Text
- View/download PDF
50. High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK/MVA-LACK regimen in Leishmania major BALB/c model of infection.
- Author
-
Sánchez-Sampedro L, Gómez CE, Mejías-Pérez E, Sorzano CO, and Esteban M
- Subjects
- Animals, Antigens, Protozoan genetics, Antigens, Protozoan immunology, Disease Models, Animal, Dogs, Immunization, Secondary methods, Leishmania major genetics, Leishmaniasis Vaccines genetics, Leishmaniasis Vaccines immunology, Leishmaniasis, Cutaneous genetics, Leishmaniasis, Cutaneous immunology, Mice, Mice, Inbred BALB C, Protozoan Proteins genetics, Protozoan Proteins immunology, Time Factors, Vaccines, DNA genetics, Vaccines, DNA immunology, Vaccines, DNA pharmacology, Vaccinia virus, Antigens, Protozoan pharmacology, CD4-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes immunology, Immunologic Memory drug effects, Leishmania major immunology, Leishmaniasis Vaccines pharmacology, Leishmaniasis, Cutaneous prevention & control, Protozoan Proteins pharmacology
- Abstract
Heterologous vaccination based on priming with a plasmid DNA vector and boosting with an attenuated vaccinia virus MVA recombinant, with both vectors expressing the Leishmania infantum LACK antigen (DNA-LACK and MVA-LACK), has shown efficacy conferring protection in murine and canine models against cutaneus and visceral leishmaniasis, but the immune parameters of protection remain ill defined. Here we performed by flow cytometry an in depth analysis of the T cell populations induced in BALB/c mice during the vaccination protocol DNA-LACK/MVA-LACK, as well as after challenge with L. major parasites. In the adaptive response, there is a polyfunctional CD4(+) and CD8(+) T cell activation against LACK antigen. At the memory phase the heterologous vaccination induces high quality LACK-specific long-term CD4(+) and CD8(+) effector memory cells. After parasite challenge, there is a moderate boosting of LACK-specific CD4(+) and CD8(+) T cells. Anti-vector responses were largely CD8(+)-mediated. The immune parameters induced against LACK and triggered by the combined vaccination DNA/MVA protocol, like polyfunctionality of CD4(+) and CD8(+) T cells with an effector phenotype, could be relevant in protection against leishmaniasis.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.